REED - Revista Española de Enfermedades Digestivas

Alerta del nuevo número	Contacto
Envío de artículos	Síguenos REEDigestivas_
English version

Año 2024 / Volumen 116 / Número 3
Revisión

Prognostic analysis of Yes-associated protein 1 in patients with colorectal cancer. A systematic review and meta-analysis

148-156

DOI: 10.17235/reed.2022.8472/2021

Hui Zhang, Mengqi Yin, Yu Hu, Mingming Jiang, Mingliang Lu, Yajuan Wu,

Resumen

Background: colorectal cancer (CRC) is the most common carcinoma worldwide, but a lack of effective prognostic markers limits clinical diagnosis and treatment. Yes-associated protein 1 (YAP1) is an effector of the HIPPO-pathway, which plays a critical role in cancer development and prognosis, including CRC. However, previous reports have suggested that it plays a dual role in CRC. Methods: a meta-analysis using RevMan 5.4 and Stata 14.0 was performed to evaluate the relationship between YAP1 and clinical outcomes of CRC, after searching for eligible studies in the PubMed, Web of Science and Embase databases. Online datasets GEPIA and LOGpc were also used to calculate survival results and for comparison with the meta-analysis results. Besides, “DESeq” packages were used for the expression analysis of YAP1 from the TCGA dataset. Results: YAP1 was overexpressed in the cancer tissues when compared to normal tissues in patients with CRC from the TCGA database (p = 0.000164) and GEPIA database. A total of 10 studies involving 2305 patients from the literature were selected. Pooled HR indicated that overexpression of YAP1 was associated with poor clinical outcomes (HR = 1.70, 95 % CI: 1.28-2.26, p = 0.0003). Subgroup analysis showed a clear correlation between overexpression of YAP1 and worse survival rate in Chinese patients (HR = 1.94, 95 % CI: 1.40-2.69, p = 0.0001), nuclear YAP1 overexpression (HR = 2.07, 95 % CI: 1.29-3.31, p = 0.003), 60 months of follow-up (HR = 1.89, 95 % CI: 1.30-2.73, p = 0.0008), IHC test (HR = 1.65, 95 % CI: 1.17-2.33, p = 0.005), IHC combined with other tests (HR = 1.77, 95 % CI: 1.13-2.77, p = 0.01) and multivariate analysis (HR = 1.70, 95 % CI: 1.24-2.31, p = 0.0009). Nevertheless, disease-free survival (DFS) showed no significant results in the patients with CRC in our meta-analysis (HR = 1.38, 95 % CI: 0.51-3.75, p = 0.52) as well as in the GEPIA and LOGpc databases. Meanwhile, YAP1 overexpression was also significantly associated with worse overall survival (OS) in GSE17536, GSE40967, GSE29623 and GSE71187. Conclusion: YAP1 overexpression is common in CRC tissues. Overexpression of YAP1 in CRC patients, particularly in the nucleus, might be related to shorter OS, maybe in the early stages. YAP1 could serve as a potential predictor of poor prognosis in CRC.

Nuevo comentario

Comentarios

No hay comentarios para este artículo.

Bibliografía

1. Read, B. and P. Sylla, Aggressive Colorectal Cancer in the Young. Clin Colon Rectal Surg, 2020. 33(5): p. 298-304.

DOI: 10.1055/s-0040-1713747

2. Recio-Boiles, A. and B. Cagir, Colon Cancer, in StatPearls. 2021: Treasure Island (FL).

3. Dekker, E., et al., Colorectal cancer. Lancet, 2019. 394(10207): p. 1467-1480.

DOI: 10.1016/S0140-6736(19)32319-0

4. Gu, M. and S. Thapa, Colorectal cancer in the United States and a review of its heterogeneity among Asian American subgroups. Asia Pac J Clin Oncol, 2020. 16(4): p. 193-200.

DOI: 10.1111/ajco.13324

5. Fisher, K.W., et al., Precision medicine in colorectal cancer: evolving genomic landscape and emerging consensus. Future Oncol, 2015. 11(19): p. 2711-2719.

DOI: 10.2217/fon.15.219

6. Hardingham, J.E., et al., Detection and Clinical Significance of Circulating Tumor Cells in Colorectal Cancer--20 Years of Progress. Mol Med, 2015. 21 Suppl 1: p. S25-31.

DOI: 10.2119/molmed.2015.00149

7. Edgar, B.A., From cell structure to transcription: Hippo forges a new path. Cell, 2006. 124(2): p. 267-73.

DOI: 10.1016/j.cell.2006.01.005

8. Hong, A.W., Z. Meng, and K.L. Guan, The Hippo pathway in intestinal regeneration and disease. Nat Rev Gastroenterol Hepatol, 2016. 13(6): p. 324-37.

DOI: 10.1038/nrgastro.2016.59

9. Meng, Z., T. Moroishi, and K.L. Guan, Mechanisms of Hippo pathway regulation. Genes Dev, 2016. 30(1): p. 1-17.

DOI: 10.1101/gad.274027.115

10. Moroishi, T., C.G. Hansen, and K.L. Guan, The emerging roles of YAP and TAZ in cancer. Nat Rev Cancer, 2015. 15(2): p. 73-79.

DOI: 10.1038/nrc3876

11. Matallanas, D., et al., RASSF1A elicits apoptosis through an MST2 pathway directing proapoptotic transcription by the p73 tumor suppressor protein. Mol Cell, 2007. 27(6): p. 962-75.

DOI: 10.1016/j.molcel.2007.08.008

12. Murakami, S., et al., Yes-associated protein mediates immune reprogramming in pancreatic ductal adenocarcinoma. Oncogene, 2017. 36(9): p. 1232-1244.

DOI: 10.1038/onc.2016.288

13. Wu, H., et al., Clinicopathological and prognostic significance of Yes-associated protein expression in hepatocellular carcinoma and hepatic cholangiocarcinoma. Tumour Biol, 2016. 37(10): p. 13499-13508.

DOI: 10.1007/s13277-016-5211-y

14. Liu, J.Y., et al., Overexpression of YAP 1 contributes to progressive features and poor prognosis of human urothelial carcinoma of the bladder. BMC Cancer, 2013. 13: p. 349.

15. Wang, Y., et al., Overexpression of yes-associated protein contributes to progression and poor prognosis of non-small-cell lung cancer. Cancer Sci, 2010. 101(5): p. 1279-85.

DOI: 10.1111/j.1349-7006.2010.01511.x

16. Yan, H., et al., Yap regulates gastric cancer survival and migration via SIRT1/Mfn2/mitophagy. Oncol Rep, 2018. 39(4): p. 1671-1681.

DOI: 10.3892/or.2018.6252

17. Konsavage, W.M., Jr., et al., Wnt/beta-catenin signaling regulates Yes-associated protein (YAP) gene expression in colorectal carcinoma cells. J Biol Chem, 2012. 287(15): p. 11730-9.

DOI: 10.1074/jbc.M111.327767

18. Yuan, M., et al., Yes-associated protein (YAP) functions as a tumor suppressor in breast. Cell Death Differ, 2008. 15(11): p. 1752-9.

DOI: 10.1038/cdd.2008.108

19. Barry, E.R., et al., Restriction of intestinal stem cell expansion and the regenerative response by YAP. Nature, 2013. 493(7430): p. 106-10.

DOI: 10.1038/nature11693

20. Cottini, F., et al., Rescue of Hippo coactivator YAP1 triggers DNA damage-induced apoptosis in hematological cancers. Nat Med, 2014. 20(6): p. 599-606.

DOI: 10.1038/nm.3562

21. Xu, Z., et al., YAP Levels Combined with Plasma CEA Levels Are Prognostic Biomarkers for Early-Clinical-Stage Patients of Colorectal Cancer. Biomed Res Int, 2019. 2019: p. 2170830.

22. Li, H.L., et al., A review: hippo signaling pathway promotes tumor invasion and metastasis by regulating target gene expression. J Cancer Res Clin Oncol, 2021. 147(6): p. 1569-1585.

DOI: 10.1007/s00432-021-03604-8

23. Dong, T., et al., High cytoplasmic YAP1 expression predicts a poor prognosis in patients with colorectal cancer. PeerJ, 2020. 8.

DOI: 10.7717/peerj.10397

24. Wang, Y., et al., Clinical and prognostic significance of Yes-associated protein in colorectal cancer. Tumour Biol, 2013. 34(4): p. 2169-74.

DOI: 10.1007/s13277-013-0751-x

25. Yang, R., et al., Tumour YAP1 and PTEN expression correlates with tumour-associated myeloid suppressor cell expansion and reduced survival in colorectal cancer. Immunology, 2018. 155(2): p. 263-272.

DOI: 10.1111/imm.12949

26. Wang, L., et al., Overexpression of YAP and TAZ is an independent predictor of prognosis in colorectal cancer and related to the proliferation and metastasis of colon cancer cells. PLoS One, 2013. 8(6): p. e65539.

DOI: 10.1371/journal.pone.0065539

27. Zhang, S., et al., Loss of Yes-associated Protein Represents an Aggressive Subtype of Colorectal Cancer. J Cancer, 2019. 10(3): p. 689-696.

DOI: 10.7150/jca.28333

28. Tierney, J.F., et al., Practical methods for incorporating summary time-to-event data into meta-analysis. Trials, 2007. 8: p. 16.

29. Kim, J.Y., et al., VGLL4 with low YAP expression is associated with favorable prognosis in colorectal cancer. Apmis, 2020. 128(10): p. 543-551.

DOI: 10.1111/apm.13070

30. Ou, C., et al., MiR-590-5p, a density-sensitive microRNA, inhibits tumorigenesis by targeting YAP1 in colorectal cancer. Cancer Letters, 2017. 399: p. 53-63.

DOI: 10.1016/j.canlet.2017.04.011

31. Sun, Z., et al., YAP1-induced MALAT1 promotes epithelial-mesenchymal transition and angiogenesis by sponging miR-126-5p in colorectal cancer. Oncogene, 2019. 38(14): p. 2627-2644.

DOI: 10.1038/s41388-018-0628-y

32. Kim, D.H., et al., Differential expression of Yes-associated protein and phosphorylated Yes-associated protein is correlated with expression of Ki-67 and phospho-ERK in colorectal adenocarcinoma. Histol Histopathol, 2013. 28(11): p. 1483-90.

33. Weinstein, P.S., et al., Acute-phase proteins or tumour markers: the role of SAA, SAP, CRP and CEA as indicators of metastasis in a broad spectrum of neoplastic diseases. Scand J Immunol, 1984. 19(3): p. 193-8.

DOI: 10.1111/j.1365-3083.1984.tb00919.x

34. Duffy, M.J., et al., Tumour markers in colorectal cancer: European Group on Tumour Markers (EGTM) guidelines for clinical use. Eur J Cancer, 2007. 43(9): p. 1348-60.

DOI: 10.1016/j.ejca.2007.03.021

35. Zhou, D., et al., Mst1 and Mst2 protein kinases restrain intestinal stem cell proliferation and colonic tumorigenesis by inhibition of Yes-associated protein (Yap) overabundance. Proc Natl Acad Sci U S A, 2011. 108(49): p. E1312-20.

DOI: 10.1073/pnas.1110428108

36. Steinhardt, A.A., et al., Expression of Yes-associated protein in common solid tumors. Hum Pathol, 2008. 39(11): p. 1582-9.

DOI: 10.1016/j.humpath.2008.04.012

1. READ B, SYLLA P. Aggressive Colorectal Cancer in the Young[J]. Clin Colon Rectal Surg, 2020,33(5):298-304.

DOI: 10.1055/s-0040-1713747

2. RECIO-BOILES A, CAGIR B. Colon Cancer. StatPearls. Treasure Island (FL)2021.

3. DEKKER E, TANIS P J, VLEUGELS J L A, et al. Colorectal cancer[J]. Lancet, 2019,394(10207):1467-1480.

DOI: 10.1016/S0140-6736(19)32319-0

4. GU M, THAPA S. Colorectal cancer in the United States and a review of its heterogeneity among Asian American subgroups[J]. Asia Pac J Clin Oncol, 2020,16(4):193-200.

DOI: 10.1111/ajco.13324

5. FISHER K W, LOPEZ-BELTRAN A, MONTIRONI R, et al. Precision medicine in colorectal cancer: evolving genomic landscape and emerging consensus[J]. Future Oncol, 2015,11(19):2711-2719.

DOI: 10.2217/fon.15.219

6. HARDINGHAM J E, GROVER P, WINTER M, et al. Detection and Clinical Significance of Circulating Tumor Cells in Colorectal Cancer--20 Years of Progress[J]. Mol Med, 2015,21 Suppl 1:S25-31.

DOI: 10.2119/molmed.2015.00149

7. EDGAR B A. From cell structure to transcription: Hippo forges a new path[J]. Cell, 2006,124(2):267-273.

DOI: 10.1016/j.cell.2006.01.005

8. HONG A W, MENG Z, GUAN K L. The Hippo pathway in intestinal regeneration and disease[J]. Nat Rev Gastroenterol Hepatol, 2016,13(6):324-337.

DOI: 10.1038/nrgastro.2016.59

9. MENG Z, MOROISHI T, GUAN K L. Mechanisms of Hippo pathway regulation[J]. Genes Dev, 2016,30(1):1-17.

DOI: 10.1101/gad.274027.115

10. MOROISHI T, HANSEN C G, GUAN K L. The emerging roles of YAP and TAZ in cancer[J]. Nat Rev Cancer, 2015,15(2):73-79.

DOI: 10.1038/nrc3876

11. MATALLANAS D, ROMANO D, YEE K, et al. RASSF1A elicits apoptosis through an MST2 pathway directing proapoptotic transcription by the p73 tumor suppressor protein[J]. Mol Cell, 2007,27(6):962-975.

DOI: 10.1016/j.molcel.2007.08.008

12. MURAKAMI S, SHAHBAZIAN D, SURANA R, et al. Yes-associated protein mediates immune reprogramming in pancreatic ductal adenocarcinoma[J]. Oncogene, 2017,36(9):1232-1244.

DOI: 10.1038/onc.2016.288

13. WU H, LIU Y, JIANG X W, et al. Clinicopathological and prognostic significance of Yes-associated protein expression in hepatocellular carcinoma and hepatic cholangiocarcinoma[J]. Tumour Biol, 2016,37(10):13499-13508.

DOI: 10.1007/s13277-016-5211-y

14. LIU J Y, LI Y H, LIN H X, et al. Overexpression of YAP 1 contributes to progressive features and poor prognosis of human urothelial carcinoma of the bladder[J]. BMC Cancer, 2013,13:349.

DOI: 10.1186/1471-2407-13-349

15. WANG Y, DONG Q, ZHANG Q, et al. Overexpression of yes-associated protein contributes to progression and poor prognosis of non-small-cell lung cancer[J]. Cancer Sci, 2010,101(5):1279-1285.

DOI: 10.1111/j.1349-7006.2010.01511.x

16. YAN H, QIU C, SUN W, et al. Yap regulates gastric cancer survival and migration via SIRT1/Mfn2/mitophagy[J]. Oncol Rep, 2018,39(4):1671-1681.

DOI: 10.3892/or.2018.6252

17. KONSAVAGE W M, JR., KYLER S L, RENNOLL S A, et al. Wnt/beta-catenin signaling regulates Yes-associated protein (YAP) gene expression in colorectal carcinoma cells[J]. J Biol Chem, 2012,287(15):11730-11739.

DOI: 10.1074/jbc.M111.327767

18. YUAN M, TOMLINSON V, LARA R, et al. Yes-associated protein (YAP) functions as a tumor suppressor in breast[J]. Cell Death Differ, 2008,15(11):1752-1759.

DOI: 10.1038/cdd.2008.108

19. BARRY E R, MORIKAWA T, BUTLER B L, et al. Restriction of intestinal stem cell expansion and the regenerative response by YAP[J]. Nature, 2013,493(7430):106-110.

DOI: 10.1038/nature11693

20. COTTINI F, HIDESHIMA T, XU C, et al. Rescue of Hippo coactivator YAP1 triggers DNA damage-induced apoptosis in hematological cancers[J]. Nat Med, 2014,20(6):599-606.

DOI: 10.1038/nm.3562

21. XU Z, WANG H, GAO L, et al. YAP Levels Combined with Plasma CEA Levels Are Prognostic Biomarkers for Early-Clinical-Stage Patients of Colorectal Cancer[J]. Biomed Res Int, 2019,2019:2170830.

DOI: 10.1155/2019/2170830

22. LI H L, LI Q Y, JIN M J, et al. A review: hippo signaling pathway promotes tumor invasion and metastasis by regulating target gene expression[J]. J Cancer Res Clin Oncol, 2021,147(6):1569-1585.

DOI: 10.1007/s00432-021-03604-8

23. DONG T, YUAN Y, XIANG X, et al. High cytoplasmic YAP1 expression predicts a poor prognosis in patients with colorectal cancer[J]. PeerJ, 2020,8.

DOI: 10.7717/peerj.10397

24. WANG Y, XIE C, LI Q, et al. Clinical and prognostic significance of Yes-associated protein in colorectal cancer[J]. Tumour Biol, 2013,34(4):2169-2174.

DOI: 10.1007/s13277-013-0751-x

25. YANG R, CAI T-T, WU X-J, et al. Tumour YAP1 and PTEN expression correlates with tumour-associated myeloid suppressor cell expansion and reduced survival in colorectal cancer[J]. Immunology, 2018,155(2):263-272.

DOI: 10.1111/imm.12949

26. WANG L, SHI S, GUO Z, et al. Overexpression of YAP and TAZ is an independent predictor of prognosis in colorectal cancer and related to the proliferation and metastasis of colon cancer cells[J]. PLoS One, 2013,8(6):e65539.

DOI: 10.1371/journal.pone.0065539

27. ZHANG S, WEI Q, YANG Y, et al. Loss of Yes-associated Protein Represents an Aggressive Subtype of Colorectal Cancer[J]. J Cancer, 2019,10(3):689-696.

DOI: 10.7150/jca.28333

28. TIERNEY J F, STEWART L A, GHERSI D, et al. Practical methods for incorporating summary time-to-event data into meta-analysis[J]. Trials, 2007,8:16.

DOI: 10.1186/1745-6215-8-16

29. KIM J Y, KIM E K, LEE W M, et al. VGLL4 with low YAP expression is associated with favorable prognosis in colorectal cancer[J]. Apmis, 2020,128(10):543-551.

DOI: 10.1111/apm.13070

30. OU C, SUN Z, PENG Q, et al. MiR-590-5p, a density-sensitive microRNA, inhibits tumorigenesis by targeting YAP1 in colorectal cancer[J]. Cancer Letters, 2017,399:53-63.

DOI: 10.1016/j.canlet.2017.04.011

31. SUN Z, OU C, LIU J, et al. YAP1-induced MALAT1 promotes epithelial-mesenchymal transition and angiogenesis by sponging miR-126-5p in colorectal cancer[J]. Oncogene, 2019,38(14):2627-2644.

DOI: 10.1038/s41388-018-0628-y

32. KIM D H, KIM S H, LEE O J, et al. Differential expression of Yes-associated protein and phosphorylated Yes-associated protein is correlated with expression of Ki-67 and phospho-ERK in colorectal adenocarcinoma[J]. Histol Histopathol, 2013,28(11):1483-1490.

33. WEINSTEIN P S, SKINNER M, SIPE J D, et al. Acute-phase proteins or tumour markers: the role of SAA, SAP, CRP and CEA as indicators of metastasis in a broad spectrum of neoplastic diseases[J]. Scand J Immunol, 1984,19(3):193-198.

DOI: 10.1111/j.1365-3083.1984.tb00919.x

34. DUFFY M J, VAN DALEN A, HAGLUND C, et al. Tumour markers in colorectal cancer: European Group on Tumour Markers (EGTM) guidelines for clinical use[J]. Eur J Cancer, 2007,43(9):1348-1360.

DOI: 10.1016/j.ejca.2007.03.021

35. ZHOU D, ZHANG Y, WU H, et al. Mst1 and Mst2 protein kinases restrain intestinal stem cell proliferation and colonic tumorigenesis by inhibition of Yes-associated protein (Yap) overabundance[J]. Proc Natl Acad Sci U S A, 2011,108(49):E1312-1320.

DOI: 10.1073/pnas.1110428108

36. STEINHARDT A A, GAYYED M F, KLEIN A P, et al. Expression of Yes-associated protein in common solid tumors[J]. Hum Pathol, 2008,39(11):1582-1589.

DOI: 10.1016/j.humpath.2008.04.012

Descargar en un gestor de citas

Descargue la cita de este artículo haciendo clic en uno de los siguientes gestores de citas:

Métrica

Este artículo ha sido visitado 515 veces.
Este artículo ha sido descargado 32 veces.

Estadísticas de Dimensions

Estadísticas de Plum Analytics

Ficha Técnica

Recibido: 26/11/2021

Aceptado: 21/09/2022

Prepublicado: 30/09/2022

Publicado: 04/03/2024

Tiempo de revisión del artículo: 295 días

Tiempo de prepublicación: 308 días

Tiempo de edición del artículo: 829 días

Este artículo aun no tiene valoraciones.

Valoración del lector:

Valora este artículo:

Envío y seguimiento de artículos

Normas de publicación

Artículos

Guías de práctica clínica

Revisiones

Artículos destacados

Envío de artículos

Información para los autores

Servicio de traducción

Tiempo editorial – Tiempo de publicación

Revista

Información para revisores

Información para anunciantes

Artículos

Guías de práctica clínica

Revisiones

Artículos destacados

Envío de artículos

Información para los autores

Servicio de traducción

Tiempo editorial – Tiempo de publicación

Revista

Información para revisores

Información para anunciantes

Artículos

Guías de práctica clínica

Revisiones

Artículos destacados

Envío de artículos

Información para los autores

Servicio de traducción

Tiempo editorial – Tiempo de publicación

Revista

Información para revisores

Información para anunciantes

Centenario REED

Open access

Artículos en prensa

Cookie	Finalidad	Caducidad	Tipo de cookie
ASP.NET_SessionId	Hacen posible el control de tráfico desde el servidor a múltiples usuarios a la vez, la identificación y el acceso como usuario.	Cierre de sesión / Fin de proyecto	Sesión
cookiesDirective	Hacen posible recordar la configuración de las cookies.	Cierre de sesión / Fin de proyecto	Sesión
vercookies	Hacen posible mostrar el aviso del uso de cookies.	Cierre de sesión / Fin de proyecto	Sesión

Descargar en un gestor de citas

Estadísticas de Dimensions

Estadísticas de Plum Analytics

Envío y seguimiento de artículos

¿Quieres recibir cada mes el boletín digital de la REED?

De acuerdo con la legislación vigente, esta publicación está destinada exclusivamente a profesionales del sector sanitario.